San Diego, California, United States
NCT Number: NCT00544713
Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery
This study will evaluate the safety and efficacy of a new artificial tear for the treatment of dry eye that may occur after LASIK surgery
Looking for future studies?
Notify MeKey information
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Candidate for bilateral LASIK surgery for myopia correction in the range of -1.00 to -8.00 diopters
Exclusion criteria
- Dry eye signs and symptoms
- Preoperative soft or rigid contact lens wear within last 7 or 30 days, respectively
- Pregnancy or planning pregnancy
- Uncontrolled systemic disease
- Use of systemic medications affecting dry eye
Treatment and study plan
Carboxymethylcellulose and Glycerin based artificial tear
DrugAs directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
Carboxymethylcellulose
DrugAs directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
Other names: Refresh Plus®
Primary outcomes
-
Post LASIK Dry Eye Symptoms as Measured by Ocular Surface Disease Index (OSDI©) Score at Day 90
Time frame: Day 90
Measured on 12 domains (categories); a 5-point scale for each domain (0 = best, no dry eye symptoms, 4 = worst, constant dry eye symptoms). Sum of the domain scores is normalized (standardized) to a severity scale of 0-100 (0 = no symptoms (best score), 100 = maximum severity (worst score)).
Secondary outcomes
-
Patient Acceptability- Percentage of Patients Who Rated Artificial Tears (AT) as Acceptable at Day 90
Time frame: Day 90
A questionnaire was administered to all patients to evaluate the acceptability of the Artificial Tears (referred to as AT). Percentage of patients responding either "Agree" or "Strongly Agree" at day 90 was tabulated. The potential response categories included "Strongly Agree", "Agree", "Neither Agree Nor Disagree", "Disagree" and "Strongly Disagree".
-
Patient Acceptability (Sensory) - Percentage of Patients Who Rated Artificial Tears (AT) as Acceptable at Day 90
Time frame: Day 90
A patient acceptability - sensory questionnaire was administered to all patients to evaluate the acceptability of the Artificial Tears (AT). Percentage of patients responding either "Agree" or "Strongly Agree" at day 90 was tabulated. The potential response categories included "Strongly Agree", "Agree", "Neither Agree Nor Disagree", "Disagree" and "Strongly Disagree".
-
Best Corrected Visual Acuity (BCVA) Status at Day 90
Time frame: Day 90
BCVA status at Day 90 reported as the number of patients whose scores were either "Better", "No Change", or "Worse" than their scores at baseline. The status was tabulated as number of lines read correctly at Day 90 minus the number of lines read correctly at baseline. "Better" equals increase of 2 lines or more; "No Change" equals change between -2 to +2 lines; "Worse" equals decrease of 2 lines or more. BCVA is measured using a special eye chart a nd is reported as the number of lines (5 letters per line) read correctly.
-
Change From Baseline of the Worse Eye in Corneal Topography as Measured by Pentacam at Day 90
Time frame: Baseline, Day 90
Change from Baseline in corneal topography of the worse eye as measured using a Pentacam system which calculates a number. Corneal topography is a non-invasive medical imaging technique for mapping the surface of the eye. The Pentacam system measures the pupil and anterior segment (the front part of the eye) which provides a range from 10 (best) to 60 (worst). A negative number change from baseline indicates an improvement.
-
Change From Baseline of the Worse Eye in Corneal Topography Measured by Humphrey Atlas at Day 90
Time frame: Baseline, Day 90
Change from Baseline in corneal topography of the worse eye as measured by a Humphrey Atlas system which calculates a number. Corneal topography is anon-invasive medical imaging technique for mapping the surface curvature of the cornea (the outer structure of the eye). The higher the number the more irregular the cornea. A Humphrey Atlas system detects irregular conditions in the cornea with a range from 0 = best to 2.5 = worst. A negative number change from baseline indicates an improvement.
-
Change From Baseline of Total Higher Order Aberration (HOA) of the Worse Eye at Day 90
Time frame: Baseline, Day 90
Change from Baseline in total HOA of the worse eye. The total HOA number is measured using a machine that calculates and detects changes in the cornea which could occur post Lasik surgery. A negative number change from baseline indicates an improvement.
-
Change From Baseline of the Worse Eye in Schirmer's Test at Day 90
Time frame: Baseline, Day 90
Change from baseline in Schirmer's Test results at Day 90 in the worse eye. The Schirmer's Test measures the rate of the secretion of tears produced by the eye over 5 minutes. The results indicate the presence of dry eye (Normal = greater than or equal to 15 millimeters (mm) of tears, Dry Eye = less than 15 mm of tears). The smaller the number, the more severe the dry eye.
-
Change From Baseline of the Worse Eye in Corneal Staining With Fluorescein at Day 90
Time frame: Baseline, Day 90
Change from Baseline in corneal staining of the worse eye at Day 90. Sum of corneal staining over 5 zones; each zone was measured on a modified Oxford Scheme (0 = no staining and 5 = severe staining), for a minimum score of 0 and a maximum score of 25. The higher the grade score, the worse the dry eye condition. A negative change from baseline represents a decrease in corneal staining (improvement).
-
Change From Baseline of the Worse Eye in Conjunctival Staining With Lissamine Green at Day 90
Time frame: Baseline, Day 90
Change from Baseline in conjunctival staining of the worse eye using Lissamine Green staining procedure. Sum of conjunctival staining over 6 zones; each zone was measured on a modified Oxford Scheme (0 = no staining and 5 = severe staining), with a minimum score of 0 and a maximum score of 30. The higher the grade score, the worse dry eye condition. A negative number change from baseline represents a decrease in corneal staining (improvement).
-
Change From Baseline of the Worse Eye in Tear Break-Up Time (TBUT) at Day 90
Time frame: Baseline, Day 90
Change from Baseline in TBUT of the worse eye at Day 90. TBUT is the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement).
-
Change From Baseline in Study Product Usage at Day 90
Time frame: Baseline, Day 90
Change from baseline in the study product usage (average number of uses per day) at Day 90. A negative number change from baseline indicates a reduction in eye drop usage (improvement).
Other outcomes
-
Number of Patients Prescribed to Each Dosing Regimen at Day 14 and Day 60
Time frame: Day 14, Day 60
Number of patients prescribed to each dosing regimen at Day 14 and Day 60. At each visit from Day 14 (the first post-operative visit) to Day 60, patients were prescribed to 1 to 4 dosing regimens based on the investigator's clinical evaluation. Dosing schedule options were: At least every 2 hours while awake, 6 to 8 times per day, 3 to 5 times per day, at 1 to 2 times per day.
Sponsors and collaborators
Lead sponsor
Allergan
Industry
Registry information
Important dates
- Study start
- 2007
- Primary completion
- 2008
- Study completion
- 2008
- First posted
- Oct 16, 2007
- Registry last updated
- Dec 14, 2011
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment
NCT04343287
Dry Eye Syndrome, Dry Eye Syndromes
Newport Beach, California, United States
View Trial DetailsSafety and Efficacy of BRM421 for Dry Eye Syndrome
NCT03066219
Dry Eye Syndrome, Dry Eye Syndromes
Lewiston, Maine, United States
View Trial DetailsPerformance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.
NCT06375499
Dry Eye Syndrome, Dry Eye Syndromes
Prague, Czechia
View Trial DetailsThe Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability
NCT01013077
Dry Eye Syndrome, Dry Eye Syndromes
Fullerton, California, United States
View Trial Details